Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Novartis digital initiatives to create awareness of heart failure can positively impact patients’ lives in India, says GlobalData

Novartis has taken a lead in actively promoting heart failure awareness across India through unbranded digital initiatives that can successfully deliver message to a large population at risk, says GlobalData, a leading data and analytics company. According to GlobalData’s Pharma Intelligence Center, the diagnosed prevalence of congestive heart failure in India is currently around 9.61 […]
Read more

COVID-19 pandemic affects development of Alzheimer’s drugs

With many countries putting clinical trials studies on hold, pharmaceutical companies are shifting their overall priorities away from some current indications toward COVID-19. This could put several Alzheimer’s Disease (AD) drugs, of which there are 38 in Phase I, 19 in Phase III and 37 in Phase II, at risk of delay, says GlobalData, a leading data and […]
Read more

Rheumatology patients treatment jeopardized by coronavirus pandemic

With the global COVID-19 pandemic, many patient groups are at an increased risk of infection and this extends to rheumatology patients prescribed immunosuppressant medication. The outbreak has presented these patients with medical and logistical difficulties that will certainly jeopardize their treatment, says GlobalData, a leading data and analytics company.  Antoine Grey, MBiochem, Senior Healthcare Analyst […]
Read more

AstraZeneca gains approval for Koselugo in rare neurological disorder after 17 years of development

Following the news that AstraZeneca’s Koselugo (selumetinib) has been approved by the US Food and Drug Administration (FDA) for the treatment of a rare neurological disorder; Philippa Salter, Neurology & Ophthalmology Analyst at GlobalData, a leading data and analytics company, offers her view: “Previous treatments for neurofibromatosis type 1 (NF1) in pediatric patients, who have […]
Read more

Fujifilm’s influenza drug favipiravir being tested to treat COVID-19

As the number of confirmed COVID-19 cases reaches nearly 1.5 million worldwide, with almost 430,000 in the US alone, the urgency of finding a treatment mounts. One of the potentially quickest ways to find treatment is to test drugs already approved or in development for other indications, says GlobalData, a leading data and analytics company. Philipp Rosenbaum, PhD, Infectious Diseases Analyst at GlobalData commented: […]
Read more

Increased availability of virtual mental health tools reported as the COVID-19 crisis continues

Use of virtual mental health tools is expected to rise significantly over the coming months as self-quarantine and social distancing measures show no signs of being lifted, says GlobalData, a leading data and analytics company. Kathryn Whitney, MSc, Director of Thematic Analysis, comments: “COVID-19 has placed enormous strain on the mental health of the general public, as well as healthcare professionals. The crisis is causing heightened anxiety and stress, with people feeling vulnerable and struggling with worries about contracting the virus, job losses and pay […]
Read more

Novo Nordisk’s dominance in GLP-1RA market to continue with arrival of Rybelsus and strong sales for Ozempic in 2019

Novo Nordisk will continue to dominate a large share of the glucagon-like peptide-1 receptor agonist (GLP-1RA) market with the arrival of Rybelsus and Ozempic’s strong global sales of $1.65bn in 2019. This will enable the company to maintain its well-established position in the wider diabetes market, according to GlobalData, a leading data and analytics company. Akash Patel MSc, Pharma Analyst at GlobalData, comments: “Ozempic (semaglutide) is an injectable GLP-1RA indicated for the treatment of type 2 diabetes (T2D). Since its US launch in February 2018, the drug’s market share has grown due to its impressive glycemic and non-glycemic benefits. The drug also […]
Read more

COVID-19 exposes fragility of global supply chains but blockchain could be missing link in building resilience, says GlobalData

The COVID-19 pandemic has disrupted nearly every part of supply chains within the healthcare industry, once again exposing the vulnerabilities of many organizations, especially those that have a high dependence on markets such as India and China to meet their raw materials or finished products’ needs. The COVID-19 outbreak is likely to result in healthcare […]
Read more

Clinical trials delayed during COVID-19, says GlobalData

There has been an increase in clinical trial delays due to concerns for patient and investigator safety, travel restrictions, subject quarantine, clinical site closures and interrupted supply chains. Numerous aspects of clinical trials are being impacted including enrolment of patients, study start times and initiation of new studies, says GlobalData, a leading data and analytics […]
Read more

Gilead’s remdesivir better suited to mild-to-moderate COVID-19 patients, says GlobalData

Gilead Sciences’ remdesivir is more likely to work in mild-to-moderate COVID-19 patients rather than severe cases, according to reporting from Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. Castañeda explains: “Given its antiviral mechanism, interviewed experts noted that remdesivir has the potential to decrease viral load in less-severe patients. […]
Read more

Intensive care units would experience severe strain from high-risk groups of COVID-19, says GlobalData

As the COVID-19 situation grows, intensive care units (ICUs) in hospitals have to handle more patients with severe cases of the virus. COVID-19 can be more severe for those individuals with pre-existing conditions such as diabetes, heart disease, chronic obstructive pulmonary disease (COPD), and asthma along with immune-compromised or older individuals. As Europe and the […]
Read more

Risk of severe COVID-19 faced by 330m people in the 9MM, says GlobalData

Coronavirus (COVID-19) has now spread across 184 countries with approximately 1.5 million total confirmed cases worldwide as of 09.04.2020; Katie Wrenn, Associate Epidemiologists at GlobalData, a leading data and analytics company, offers her view on the current challenges facing the 9MM: “We now know that severe and critical forms of COVID-19 are more common in the elderly […]
Read more

COVID-19 leads to unpredictable IPOs and venture financing deals for biopharma companies, says GlobalData

In this unprecedented time of uncertainty, key markets have lost 20–70% of their value year-to-date due to COVID-19, according to GlobalData’s COVID-19 Executive Briefing. Sharon Cartic, Associate Director for Drugs and Business Fundamentals Databases at GlobalData, comments: “This drop in value is inevitably having an impact on the initial public offerings (IPOs) of biopharma companies […]
Read more

Hydroxychloroquine for COVID-19 needs more data

As COVID-19 spreads, the search for a treatment is ramping up. The antimalarial and immunosuppressant hydroxychloroquine has received some attention, including that of President Trump. There are currently around 60 planned or in-progress clinical trials to test its efficacy as a treatment for COVID-19. However, the results of recently completed clinical trials indicate there are not enough data to support hydroxychloroquine use for COVID-19 treatment at the level of expectations […]
Read more

Amgen and Adaptive Biotechnologies join a long list of drug and vaccine development partnerships to combat COVID-19

With the advent of COVID-19 reaching over one million cases worldwide, a concerted effort will be needed to approach this growing problem.  Drug development partnerships between companies that complement their areas of expertise will more rapidly facilitate research on this disease, says GlobalData. Philipp Rosenbaum, PhD, Infectious Diseases Analyst at GlobalData, commented: “While past historical data […]
Read more
1 … 98 99 100 101 102 … 110